WESTLAKE VILLAGE, Calif., March 2, 2016 /PRNewswire/ -- Envy Medical, Inc., a leader in the field of dermatology, medical aesthetics and professional skincare, is pleased to announce the appointment of Arash A. Khazei as its Chief Executive Officer.
With a strategically planned transition, Mr. Khazei replaces Curtis A. Cluff, who has resigned and will be leaving to pursue other business opportunities after transitioning his responsibilities. Chairman of the Board and founder, Ken Karasiuk, remarked, "We wish to thank Curtis for his accomplishments as Envy's CEO over the last seven years. Through Curtis' dedicated leadership, Envy has significantly expanded its distribution in the United States and to more than 35 countries around the world." Mr. Karasiuk adds, "Arash's expertise promises to play a crucial role in our next phase of growth. With keen insight and a unique ability to nurture and promote Envy's global strategy, Arash's proven track record will enable us to execute and bring Envy to the next level."
Mr. Khazei joins Envy from L'Oreal, where he was Senior Vice President managing the financial operation and integration of NYX Cosmetics subsequent to its acquisition by L'Oreal in 2014. Mr. Khazei entered NYX as its Chief Financial Officer in 2010 and was instrumental in the growth of NYX Cosmetics over the last six years. During his tenure, he helped to globalize the NYX brand in over 40 countries through professional, mass and specialty retailers such as ULTA, Target, CVS, and Sephora. Prior to joining NYX, Mr. Khazei was Executive Vice President and Chief Financial Officer of United PanAm Financial Corporation (UPFC), a publicly traded consumer finance company. At UPFC he built the retail infrastructure that facilitated the company's expansion from 90 to over 140 locations in 70 markets. Arash began his professional career working at Arthur Andersen LLP and the Walt Disney Corporation.
"It's a privilege to join the seasoned team at Envy Medical," said Mr. Khazei. "I look forward to applying past successful experiences to support Envy's robust growth strategy while continuing to position the company as a pioneer and leader in Face and Body medical treatments and Skincare."
ABOUT ENVY MEDICAL
Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company's lead products include SilkPeel®, a breakthrough device combining exfoliation with Advanced Dermalinfusion® Technology for deeper tissue delivery of active ingredients and better patient outcomes (www.silkpeel.com). Envy is also the developer of the patent pending ClarityMD® Acne Solution brand of acne treatment products (www.claritymdacne.com) and is the exclusive worldwide licensor of skin brightening peptides, including the Lumixyl® peptide, developed at Stanford University (www.lumixyl.com). More information can be found at envymedical.com.
SOURCE Envy Medical, Inc.